Co-Authors
This is a "connection" page, showing publications co-authored by VICTOR PRIETO and MICHAEL A DAVIES.
Connection Strength
1.047
-
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014 Nov 01; 20(21):5537-46.
Score: 0.120
-
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. 2012 Feb 15; 18(4):1120-8.
Score: 0.102
-
A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008 Oct 21; 99(8):1265-8.
Score: 0.081
-
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23.
Score: 0.055
-
Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
Score: 0.054
-
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).
Score: 0.049
-
Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
Score: 0.043
-
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
Score: 0.041
-
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
Score: 0.041
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.041
-
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086.
Score: 0.038
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.037
-
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.
Score: 0.036
-
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016 09; 240(1):84-95.
Score: 0.035
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.035
-
Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.
Score: 0.034
-
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
Score: 0.032
-
Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
Score: 0.032
-
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
Score: 0.031
-
Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol. 2014; 1102:679-95.
Score: 0.029
-
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
Score: 0.027
-
Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. J Cutan Pathol. 2012 May; 39(5):493-9.
Score: 0.026
-
Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol. 2012 May; 180(5):2170-81.
Score: 0.026